Blackstone Inc’s Acadia Pharmaceuticals ACAD Stock Holding History

Blackstone Inc’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$336K	Sell	13,286 -7	-0.1%	-$154	﹤0.01%	435
2026 Q1	$296K	Buy	+13,293	New	+$318K	﹤0.01%	352

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Blackstone Inc's ACAD Position: Q2 2026 in Review

Blackstone Inc reduced its Acadia Pharmaceuticals (ACAD) stake by 0.05% in Q2 2026, selling an estimated $154 and leaving 13,286 shares worth $336K. The position accounts for ﹤0.01% of the portfolio, ranked #435.

Blackstone Inc first reported a position in ACAD in Q1 2026 and has held it in 2 quarters since. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

Blackstone Inc held 13,286 shares of Acadia Pharmaceuticals worth $336K as of Q2 2026.
Blackstone Inc sold 7 Acadia Pharmaceuticals shares in Q2 2026, an estimated $154.
Acadia Pharmaceuticals made up ﹤0.01% of Blackstone Inc's portfolio in Q2 2026, its #435 holding.
Blackstone Inc first reported a position in Acadia Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Blackstone Inc's 13F filing for Q2 2026, filed 14 Aug 2026.